– Execution on turnaround plan translates into visible productivity improvements in Care Delivery achieving a Q2 margin at the lower end of the 2025 target margin band
– Savings resulting from FME25 transformation program fully on track
– Successful execution on portfolio optimization strategy
– Legal form conversion to a German Stock Corporation approved by shareholders
– FY 2023 operating income guidance range narrowed
Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: “The second quarter makes evident that the execution against our strategic plan is fully on track. We are executing on our portfolio optimization, continuing to deliver on our FME25 program and are accelerating our turnaround activities. As expected, we have seen a stabilization of the labor market and of the inflationary environment. Our measures to increase productivity, supported by the targeted clinic closures, are driving a positive development. This gives us the confidence to narrow our operating income guidance range to the upper part for the year.”
For more information see attachment.
Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Telefon: +49 (6172) 609-0
Telefax: +49 (6172) 609-2301
http://www.fmc-ag.de
Media contact
Telefon: +49 (6172) 608-4030
E-Mail: leif.heussen@fresenius.com
Telefon: +49 (6172) 609-2601
E-Mail: dominik.heger@fmc-ag.com